Skip to main content
NCBI home page
Canadian Family Physician logoLink to Canadian Family Physician
. 2000 Feb;46:322-6, 330-6.

Olanzapine. Keep an eye on this neuroleptic.

PMCID: PMC1987672  PMID: 10690489

Abstract

Olanzapine (Zyprexa), a neuroleptic, has obtained marketing authorization for treatment of schizophrenia. The clinical file is satisfactory, but in the absence of relevant trials, it has not yet been demonstrated that olanzapine has a specific activity on the positive or negative symptoms of schizophrenia. The global efficacy of olanzapine was not substantially different from that of haloperidol in two of the three comparative trials published to date. The only relevant comparative trial fails to demonstrate the superiority of olanzapine over risperidone. Olanzapine has fewer adverse neurologic effects than haloperidol, but there is no evidence that it differs from other recent neuroleptics in this respect. Olanzapine can have anticholinergic adverse effects and frequently causes weight gain. Active surveillance is required because subclinical cases of elevated transaminase levels, increased blood pressure, and QT prolongation were observed in clinical trials (2500 patients treated).

Full text

PDF
322

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beasley C. M., Jr, Hamilton S. H., Crawford A. M., Dellva M. A., Tollefson G. D., Tran P. V., Blin O., Beuzen J. N. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. 1997 May;7(2):125–137. doi: 10.1016/s0924-977x(96)00392-6. [DOI] [PubMed] [Google Scholar]
  2. Beasley C. M., Jr, Hamilton S. H., Crawford A. M., Dellva M. A., Tollefson G. D., Tran P. V., Blin O., Beuzen J. N. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. 1997 May;7(2):125–137. doi: 10.1016/s0924-977x(96)00392-6. [DOI] [PubMed] [Google Scholar]
  3. Beasley C. M., Jr, Sanger T., Satterlee W., Tollefson G., Tran P., Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996 Mar;124(1-2):159–167. doi: 10.1007/BF02245617. [DOI] [PubMed] [Google Scholar]
  4. Beasley C. M., Jr, Sanger T., Satterlee W., Tollefson G., Tran P., Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996 Mar;124(1-2):159–167. doi: 10.1007/BF02245617. [DOI] [PubMed] [Google Scholar]
  5. Beasley C. M., Jr, Tollefson G. D., Tran P. V. Safety of olanzapine. J Clin Psychiatry. 1997;58 (Suppl 10):13–17. [PubMed] [Google Scholar]
  6. Beasley C. M., Jr, Tollefson G. D., Tran P. V. Safety of olanzapine. J Clin Psychiatry. 1997;58 (Suppl 10):13–17. [PubMed] [Google Scholar]
  7. Beasley C. M., Jr, Tollefson G., Tran P., Satterlee W., Sanger T., Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996 Feb;14(2):111–123. doi: 10.1016/0893-133X(95)00069-P. [DOI] [PubMed] [Google Scholar]
  8. Beasley C. M., Jr, Tollefson G., Tran P., Satterlee W., Sanger T., Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996 Feb;14(2):111–123. doi: 10.1016/0893-133X(95)00069-P. [DOI] [PubMed] [Google Scholar]
  9. Conley R. R., Tamminga C. A., Bartko J. J., Richardson C., Peszke M., Lingle J., Hegerty J., Love R., Gounaris C., Zaremba S. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry. 1998 Jul;155(7):914–920. doi: 10.1176/ajp.155.7.914. [DOI] [PubMed] [Google Scholar]
  10. Conley R. R., Tamminga C. A., Bartko J. J., Richardson C., Peszke M., Lingle J., Hegerty J., Love R., Gounaris C., Zaremba S. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry. 1998 Jul;155(7):914–920. doi: 10.1176/ajp.155.7.914. [DOI] [PubMed] [Google Scholar]
  11. Dellva M. A., Tran P., Tollefson G. D., Wentley A. L., Beasley C. M., Jr Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv. 1997 Dec;48(12):1571–1577. doi: 10.1176/ps.48.12.1571. [DOI] [PubMed] [Google Scholar]
  12. Dellva M. A., Tran P., Tollefson G. D., Wentley A. L., Beasley C. M., Jr Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv. 1997 Dec;48(12):1571–1577. doi: 10.1176/ps.48.12.1571. [DOI] [PubMed] [Google Scholar]
  13. Tollefson G. D., Beasley C. M., Jr, Tran P. V., Street J. S., Krueger J. A., Tamura R. N., Graffeo K. A., Thieme M. E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997 Apr;154(4):457–465. doi: 10.1176/ajp.154.4.457. [DOI] [PubMed] [Google Scholar]
  14. Tollefson G. D., Beasley C. M., Jr, Tran P. V., Street J. S., Krueger J. A., Tamura R. N., Graffeo K. A., Thieme M. E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997 Apr;154(4):457–465. doi: 10.1176/ajp.154.4.457. [DOI] [PubMed] [Google Scholar]
  15. Tollefson G. D., Sanger T. M., Lu Y., Thieme M. E. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry. 1998 Mar;55(3):250–258. doi: 10.1001/archpsyc.55.3.250. [DOI] [PubMed] [Google Scholar]
  16. Tollefson G. D., Sanger T. M., Lu Y., Thieme M. E. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry. 1998 Mar;55(3):250–258. doi: 10.1001/archpsyc.55.3.250. [DOI] [PubMed] [Google Scholar]
  17. Tran P. V., Hamilton S. H., Kuntz A. J., Potvin J. H., Andersen S. W., Beasley C., Jr, Tollefson G. D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997 Oct;17(5):407–418. doi: 10.1097/00004714-199710000-00010. [DOI] [PubMed] [Google Scholar]
  18. Tran P. V., Hamilton S. H., Kuntz A. J., Potvin J. H., Andersen S. W., Beasley C., Jr, Tollefson G. D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997 Oct;17(5):407–418. doi: 10.1097/00004714-199710000-00010. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES